Octimet

Octimet is a startup based in Germany. Brouky classifies it under Healthcare & Life Sciences.

Octimet Oncology NV develops targeted cancer therapies by creating selective inhibitors such as OMO-1, a MET kinase inhibitor, and OMO-2, a dual MET and RAS pathway inhibitor, aimed at treating lung cancer and other oncology indications.